首页 | 本学科首页   官方微博 | 高级检索  
     


Biliary cancer: Utility of next‐generation sequencing for clinical management
Authors:Milind Javle MD  Tanios Bekaii‐Saab MD  Apurva Jain MBBS  Ying Wang PhD  Robin Katie Kelley MD  Kai Wang MD  PhD  Hyunseon C. Kang MD  PhD  Daniel Catenacci MD  Siraj Ali MD  PhD  Sunil Krishnan MD  FACP  Daniel Ahn DO  Andrea Grace Bocobo BS  Mingxin Zuo PhD  Ahmed Kaseb MD  Vincent Miller MD  Philip J. Stephens PhD  Funda Meric‐Bernstam MD  Rachna Shroff MD  Jeffrey Ross MD
Affiliation:1. Department of Gastrointestinal (GI) Medical Oncology, UT‐MD Anderson Cancer Center, Houston, Texas;2. Division of Medical Oncology, Ohio State University Medical Center, Columbus, Ohio;3. Department of Bioinformatics & Computational Biology, UT‐MD Anderson Cancer Center, Houston, Texas;4. Department of Medicine (Hematology/Oncology), UCSF, San Francisco, California;5. Foundation Medicine, Inc., Cambridge, Massachusetts;6. Department of Diagnostic Radiology, UT‐MD Anderson Cancer Center, Houston, Texas;7. Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois;8. Department of Radiation Oncology, UT‐MD Anderson Cancer Center, Houston, Texas;9. Department of Investigational Cancer Therapeutics, UT‐MD Anderson Cancer Center, Houston, Texas;10. Department of Pathology, Albany Medical College Albany, New York
Abstract:
Keywords:AT‐rich interactive domain‐containing protein 1A (ARID1A)  biliary tract cancers  comprehensive genomic profiling  fibroblast growth factor receptor 2 (FGFR2)  isocitrate dehydrogenase 1/2 (IDH1/2)  prognosis  targeted therapy
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号